THE PROMISE STUDY: AN EVALUATION OF THE SAFETY AND ACCURACY OF THE NEXT GENERATION 180-DAY LONG-TERM IMPLANTABLE EVERSENSE CGM SYSTEM

被引：0
|
作者：
Garg, S. [1 ]
Liljenquist, D. [2 ]
Bode, B. [3 ]
Christiansen, M. [4 ]
Bailey, T. [5 ]
Brazg, R. [6 ]
Denham, D. [7 ]
Chang, A. [8 ]
Akturk, H. [9 ]
Dehennis, A. [10 ]
Tweden, K. [11 ]
Kaufman, F. [12 ]
机构：
[1] Barbara Davis Ctr Childhood Diabet, Endocrinol, Aurora, CO USA
[2] Rocky Mt Diabet Ctr, Res, Idaho Falls, ID USA
[3] Atlanta Diabet Associates, Endocrinol, Atlanta, GA USA
[4] Diablo Clin Res, Endocrinol, Walnut Creek, CA USA
[5] AMCR Inst, Clin Res, Escondido, CA USA
[6] Rainier Clin Res Ctr, Endocrinol, Renton, WA USA
[7] Clin Trials Texas Inc, Res, San Antonio, TX USA
[8] John Muir Hlth, Res, Concord, CA USA
[9] Univ Colorado, Barbara Davis Ctr Diabet, Aurora, CO USA
[10] Senseonics Inc, Engn, Germantown, MD USA
[11] Senseonics Inc, Clin Sci, Germantown, MD USA
[12] Senseonics Inc, Med Affairs, Germantown, MD USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2021年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O052 / #71
引用
收藏
页码：A36 / A37
页数：2
相关论文
共 50 条
  • [1] Evaluation of accuracy and safety of the next generation 180-day long-term implantable Eversense CGM system: the PROMISE Study
    Garg, S.
    Liljenquist, D.
    Bode, B.
    Christiansen, M.
    Bailey, T.
    Brazg, R.
    Denham, D.
    Chang, A. R.
    Akturk, H.
    Dehennis, A.
    Tweden, K. S.
    Kaufman, F. R.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 123 - 124
  • [2] Evaluation of the Next Generation 180-Day Long-Term Implantable Eversense CGM System: PROMISE Study
    Garg, Satish K.
    Liljenquist, David R.
    Bode, Bruce W.
    Christiansen, Mark P.
    Bailey, Timothy S.
    Brazg, Ronald L.
    Denham, Douglas S.
    Chang, Anna
    Akturk, Halis K.
    Dehennis, Andrew D.
    Tweden, Katherine
    Kaufman, Francine R.
    [J]. DIABETES, 2021, 70
  • [3] Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study
    Garg, Satish K.
    Liljenquist, David
    Bode, Bruce
    Christiansen, Mark P.
    Bailey, Timothy S.
    Brazg, Ronald L.
    Denham, Douglas S.
    Chang, Anna R.
    Akturk, Halis
    Dehennis, Andrew
    Tweden, Katherine S.
    Kaufman, Francine R.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 (02) : 84 - 92
  • [4] Real-World Evaluation of the Implantable 180-Day Eversense E3 CGM System
    Tweden, Katherine S.
    Romarowski, Ben
    Mdingi, Colleen
    Kaufman, Francine R.
    [J]. DIABETES, 2024, 73
  • [5] Effect of Calibration Frequency on Accuracy of a 180-Day Implantable CGM System
    Jacquin, Arnaud E.
    Al-Khawi, Lujain
    Ghosh-Dastidar, Samanwoy
    Tweden, Katherine S.
    Kaufman, Francine R.
    [J]. DIABETES, 2022, 71
  • [6] LONG-TERM SAFETY EVALUATION OF THE 90-DAY EVERSENSE CGM SYSTEM IN THE USPOST APPROVAL SETTING
    Latif, K.
    Warren, M.
    Oiknine, R.
    Mann, P.
    Tweden, K.
    Kaufman, F.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A156 - A156
  • [7] Long-term safety of the Eversense® CGM system: PMCF registry
    Kaufman, F. R.
    Tweden, K.
    Haridas, H.
    Carlson, G.
    [J]. DIABETOLOGIA, 2019, 62 : S434 - S435
  • [8] LONGEVITY OF AN IMPLANTABLE CGM SYSTEM DURING A 180 DAY STUDY
    Aronson, R.
    Mdingi, C.
    Chen, X. O.
    Abitbol, A.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A21 - A22
  • [9] Safety of Microdose Dexamethasone Acetate in the Eversense Long-Term Implantable Continuous Glucose Monitoring System
    Kelley, E. L.
    Haridas, Haritha
    Lorenz, Carrie
    [J]. DIABETES, 2018, 67
  • [10] CALIBRATION POINT ACCURACY CHARACTERIZATION ON THE PERFORMANCE OF A LONG-TERM, IMPLANTABLE CGM: A SUBANALYSIS OF THE PRECISE STUDY
    Kropff, J.
    DeVries, J. H.
    Rastogi, R.
    Dehennis, A.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A75 - A75
12345